The global bronchodilators market was valued at USD 22.2 billion in 2022 and it is predicted to surpass around USD 30.72 billion by 2032 with a CAGR of 3.3% from 2023 to 2032.
Key Pointers
Report Coverage | Details |
Market Size in 2022 | USD 22.2 billion |
Revenue Forecast by 2032 | USD 30.72 billion |
Growth rate from 2023 to 2032 | CAGR of 3.3% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
The bronchodilators market is witnessing growth due to factors such as the growing geriatric population, increasing prevalence of lung diseases, and rising awareness about lung disease treatment aided by escalating R&D efforts by key players operating in the market.
The U.S. market is expected to expand at a compound annual growth rate (CAGR) of 2.91% from 2022 to 2030. The COVID-19 outbreak had a positive impact on the market which can be attributed to the off-label use of bronchodilators for inpatient treatment. Moreover, SARS-CoV-2 weakened the lungs & immunity in patients making them susceptible to lung diseases and viral infections. For instance, as per NCBI in 2020, rhinovirus is the cause of 83% of exacerbations of wheezing in adults which facilitates the demand for nebulizers.
Growing geriatric population globally is expected to act as a key driver for the market as the elderly population has a five times higher mortality rate attributed to asthma and thus requires enhanced support from bronchodilators. Moreover, the number of people aged over 65 is anticipated to triple by 2025 and is projected to aid the bronchodilators market to become profitable.
Furthermore, the development of advanced products is majorly driven by the rising prevalence of respiratory disorders worldwide. Bronchodilators help in relieving the symptoms of respiratory disorders such as asthma and COPD, by opening the airways and counteracting the effects of an attack. This is causing a surge in product approval and launches for treating and managing respiratory disorders which is estimated to supplement the segment growth.
However, the market is significantly hampered owing to the regulatory framework related to bronchodilators. The regulatory approval procedure is frequently critiqued for being excessively slow or lenient when safety issues arise. The regulatory atmosphere is already complex, and the FDA is becoming ever more careful as dependency on bronchodilators is growing. Hence, the stringency of regulations associated with the approval process for bronchodilators is limiting the market growth. Moreover, in December 2022, the U.S. faced a shortage of albuterol inhalers demonstrating an unmet need that can be fulfilled by new generic companies.
Key Companies and Market Share Insights
The key players operating in the bronchodilators market are focusing on partnerships, geographical expansion, and strategic collaborations in emerging and economically favorable regions. For Instance, in October 2022, AeroRx Therapeutics collaborated with HCmed Innovations for the development of novel therapeutics combination of bronchodilators for the treatment of people with COPD. Some of the prominent players in the global bronchodilators market include:
Bronchodilators Market Segmentations:
By Drug Class | By Route of Administration | By Disease |
Beta-Adrenergic Bronchodilators Xanthine Derivatives Anticholinergic Bronchodilators |
Oral Nasal (Inhalable) Injectable |
Asthma Chronic Obstructive Pulmonary Disease (COPD) Others |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Bronchodilators Market
5.1. COVID-19 Landscape: Bronchodilators Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Bronchodilators Market, By Drug Class
8.1. Bronchodilators Market, by Drug Class, 2023-2032
8.1.1 Beta-Adrenergic Bronchodilators
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Xanthine Derivatives
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Anticholinergic Bronchodilators
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Bronchodilators Market, By Route of Administration
9.1. Bronchodilators Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Nasal (Inhalable)
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Bronchodilators Market, By Disease
10.1. Bronchodilators Market, by Disease, 2023-2032
10.1.1. Asthma
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Chronic Obstructive Pulmonary Disease (COPD)
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Bronchodilators Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.3. Market Revenue and Forecast, by Disease (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Disease (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.3. Market Revenue and Forecast, by Disease (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Disease (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Disease (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Disease (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.3. Market Revenue and Forecast, by Disease (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Disease (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Disease (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Disease (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Disease (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Disease (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Disease (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.3. Market Revenue and Forecast, by Disease (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Disease (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Disease (2020-2032)
Chapter 12. Company Profiles
12.1. GSK plc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AstraZeneca
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Teva Pharmaceutical Industries Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cipla Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Mylan N.V.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck & Co., Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Boehringer Ingelheim International GmbH.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sun Pharmaceutical Industries Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Glenmark Pharmaceuticals Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms